Manifold Secures $18 Million Series B to Expand AI-Driven Life Sciences Platform

Manifold, a Newton, Massachusetts‑based artificial intelligence platform for the life sciences, has secured a significant new fundraising milestone that underscores the growing investor confidence in specialized AI for biomedical research and drug development. In December 2025, the company announced it had raised $18 million in a Series B funding round, bringing its total capital raised to approximately $40 million since inception.

The Series B round was led by Reach Capital, a venture firm known for backing transformative technology companies, including those at the intersection of health, education, and digital infrastructure. Participation in the round also came from SilverArc Capital, Industry Ventures, and existing backers TQ Ventures and Calibrate Ventures.

Manifold’s funding comes at a time when the life sciences industry — a sector valued at roughly $2 trillion — increasingly seeks AI‑driven solutions to tackle longstanding productivity bottlenecks. Unlike general‑purpose AI tools, Manifold’s platform is designed specifically for life sciences workflows, helping biopharmaceutical companies, academic medical centers, and research institutions accelerate tasks from target identification and biomarker discovery to clinical development and precision care.

According to company leadership, the latest capital will be used to expand core platform capabilities, particularly around what Manifold calls its Agent OS — a suite of AI agents that operate on complex biomedical datasets, scientific tools, and institutional knowledge to accelerate insight generation. The funding will also support deeper collaboration infrastructure to allow cross‑organizational work with secure data governance, as well as scaling the broader life sciences data ecosystem to enable shared insights without compromising ownership.

Manifold’s platform has already seen broad adoption, with thousands of researchers using its tools across hundreds of organizations globally. The company cites strategic collaborations with notable scientific and technology partners, including the Broad Institute, Amazon Web Services (AWS), and Anthropic, while research organizations such as Foundation Medicine and the University of Virginia are among its early customers. Manifold also operates within Terra — a cloud platform for biomedical research — further extending its reach in the scientific community.

Jennifer Carolan, Partner at Reach Capital and lead investor in the Series B, emphasized the unique value of Manifold’s offering in a competitive and complex market. “In every industry, companies that combine agentic AI and domain‑specific context will transform productivity,” Carolan said, highlighting the importance of vertical AI systems that deeply understand sector‑specific data and workflows, particularly in life sciences.

Manifold was founded with a mission to help life sciences professionals reduce the time spent on manual, technical, and administrative tasks — freeing up expert attention for higher‑value scientific work. The company’s leadership team, including CEO Vinay Seth Mohta, has guided its evolution from early AI lab origins into a platform provider that seeks to transform how scientific research and clinical development operate in the digital era.

Investors backing Manifold reflect a blend of venture capital and sector‑specific expertise. In addition to Reach Capital, the investor base includes SilverArc Capital, a growth‑oriented investment firm focused on technology and healthcare; Industry Ventures, a global venture capital and private equity firm; TQ Ventures, which invests in early‑stage technology companies; and Calibrate Ventures, a fund that supports companies in the healthcare and life sciences innovation ecosystem.

The latest funding is the latest in a series of financing events for Manifold. Prior to this Series B, the company completed earlier rounds — including a Series A and seed investments — that helped lay the foundation for its current growth trajectory and customer momentum.

As interest in domain‑specific AI continues to grow across industries, Manifold’s successful Series B highlights how investors are betting on specialized platforms that can meaningfully enhance scientific productivity and help accelerate the delivery of life‑changing medicines to patients.